CTO of a newly formed CAR T-cell therapy company, before that he was vice president, cell therapy operations at Enara Bio. Erik holds a Ph.D. in medicine (immunology) from the University of Leiden. He was previously at Novartis, where he played a critical role in the development of KYMRIAH, the first engineered T-cell therapy to be approved by the FDA.